Our client’s key pipeline agent is in development for treatment of COVID-19 and severe community acquired pneumonia (sCAP). The company was preparing to enter Phase III in both indications. As such, the client was interested in understanding the competitive landscape of therapeutics in development in these 2 indications primarily in the US and EU5, with a wider look at ‘global’ developments.
This project was meant to arm our client with a deeper, clearer, and up to date picture of the COVID-19 and sCAP landscapes and relative opportunity to drive competitive strategic positioning/value for its pipeline agent. Of particular interest are competitive landscape changes due to development of novel assets in late clinical stage development (Phase II and above).
Our Solution
GlobalData leveraged its expertise, in-house proprietary data platforms, as well as secondary and primary qualitative market intelligence services to help our client fully understand the COVID-19 and sCAP therapeutic market (excl. immunization and prophylactic markets) and opportunities within the space.
- Market-focused secondary market research (SMR) landscape assessment for therapeutics.
- Primary qualitative market intelligence research (PMR).
- Distil feedback, identify insights, analyze threat levels and collate recommendations in preparing final deliverables.
Outcome
GlobalData delivered an Excel based prioritization model detailing the level of threat of marketed/pipeline assets (with all relevant raw data) as well as a PPT deliverable including key primary and secondary insights, prioritization output and conclusions.
The core deliverables acted as the corner stone of our client’s development and commercial planning efforts, informing board level decisions for their key asset.
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
